首页工具

Olaparib

产品编号 T3015 CAS 763113-22-0

别名: AZD2281, 奥拉帕尼, KU0059436

Olaparib (KU0059436) 是 PARP1/PARP2 的小分子抑制剂 (IC50=5/1 nM)，对 PARP tankyrase-1 的抑制活性较弱 (IC50=1.5 μM)，具有选择性和口服活性。Olaparib 具有自噬和线粒体自噬激活活性。

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Olaparib, CAS 763113-22-0

规格	价格/CNY	货期
10 mg	￥ 396	现货
50 mg	￥ 995	现货
100 mg	￥ 1,597	现货
200 mg	￥ 2,398	现货
500 mg	￥ 3,997	现货
1 g	￥ 5,500	现货
1 mL * 10 mM (in DMSO)	￥ 282	现货

大包装超大折扣，点击咨询

其他形式的 Olaparib:

Olaparib-d5
询价

选择批次

纯度: 100%

纯度: 99.89%

纯度: 99.82%

纯度: 99.65%

纯度: 99.61%

纯度: 98%

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

相关产品

拓展阅读

产品描述	Olaparib (KU0059436) is a small molecule inhibitor of PARP1/PARP2 (IC50=5/1 nM), with weak inhibitory activity against PARP tankyrase-1 (IC50=1.5 μM), and is selective and orally active. Olaparib exhibits autophagy and mitochondrial autophagy activation activity.
靶点活性	PARP2:1 nM (cell free), PARP1:5 nM (cell free)
体外活性	方法：人子宫颈癌细胞 SiHa 和 ME180 用 Olaparib (5-10 µM) 和 cisplatin (1-30 µM) 处理 72 h，使用 MTT 方法检测细胞生长抑制情况。结果：Olaparib 和 cisplatin 共同处理比用单一药物处理的细胞显示出显著的细胞生长抑制作用。[1] 方法：人子宫内膜癌细胞 HEC-6 和 HEC-6-PTEN 用 Olaparib (10 μM) 处理 72 h，使用 Flow Cytometry 方法分析细胞周期情况。结果：Olaparib 诱导 HEC-6 和 HEC-6-PTEN 细胞显著增加了亚 G1 群体。[2] 方法：鸡淋巴瘤细胞 DT40 用 Olaparib (0.01-10 μM) 处理 30 min，使用 Western Blot 方法检测靶点蛋白表达水平。结果：Olaparib 剂量依赖性抑制 PARylation 的表达水平，抑制 PARP 的活化。[3]
体内活性	方法：为检测体内抗肿瘤活性，将 Olaparib (10 mg/kg) 和 TMZ (50 mg/kg) 口服给药给携带人结直肠癌肿瘤 SW620 的小鼠，每天一次，持续五天。结果：与单独 TMZ 组相比，TMZ 加 Olaparib 组合治疗组观察到肿瘤体积的显著抑制。[4] 方法：为研究 Olaparib 对哮喘的治疗作用，将 Olaparib (1-10 mg/kg) 腹腔注射给基于 OVA 的哮喘 C57BL/6 小鼠模型，每天一次，持续三天。结果：Olaparib 能显著减少气道嗜酸性粒细胞增多、粘液产生和高反应性。Olaparib 的保护作用与抑制 Th2 细胞因子 eotaxin、IL-4、IL-5、IL-6、IL-13 和 M-CSF 以及卵清蛋白特异性 IgE 有关，同时增加 Th1 细胞因子 IFN-γ。Olaparib 有可能成为人类哮喘临床试验的候选药物。[5]
激酶实验	This assay determined the ability of test compounds to inhibit PARP-1 enzyme activity. The method that was used was as reported. We measured PARP-2 activity inhibition by using a variation of the PARP-1 assay in which PARP-2 protein (recombinant) was bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity was measured following 3H-NAD+ DNA additions. After washing, scintillant was added to measure 3 H-incorporated ribosylations. For tankyrase-1, an AlphaScreen assay was developed in which HIS-tagged recombinant TANK-1 protein was incubated with biotinylated NAD+ in a 384-well ProxiPlate assay. Alpha beads were added to bind the HIS and biotin tags to create a proximity signal, whereas the inhibition of TANK-1 activity was directly proportional to the loss of this signal. All experiments were repeated at least three times [1].
细胞实验	HSC-2, Ca9-22, and SAS oral carcinoma cells were seeded in 24-well plates at a density of 2 × 104 cells/well. After overnight incubation, the culture medium was replaced with fresh medium containing various concentrations of PARP inhibitor AZD228 or cisplatin. After 24 h of treatment, the number of viable cells was assessed using an MTT assay as reported previously. Briefly, one-tenth of the fluid volume of 5 mg/mL MTT in RPMI-1640 medium was added to each well, followed by incubation for 4 h at 37 °C. After incubation, the medium was carefully removed and an adequate volume of 0.1 N HCl in isopropanol was added to each well and the resultant formazan crystals was dissolved. Absorbance was determined at 570 nm by microplate reader in 96-well assay plates. All experiments were performed in triplicate [2].
动物实验	Once the tumor diameter had reached 7 mm, the mice were randomly assigned to the following groups: (a) control (200 μL saline); (b) cisplatin (2 mg/kg per body weight, dissolved in 200 μL sterilized water); (c) AZD2281 (25 mg/kg per body weight, dissolved in 200 μL sterilized water); or (d) combination (both cisplatin and AZD2281). The chemicals were administered intraperitoneally every three days, five times. Although AZD2281 is administered orally in the clinic, intraperitoneal injection was recommended by the manufacturer because of easier manipulation and the ethical constraints associated with oral gavage administration to mice. Tumor size and body weight were measured at the time of administration. The tumor volume was calculated using following equation. Tumor volume = verticality × width × height × 0.5236. Three days after the last administration, all surviving mice were sacrificed [2].

别名	AZD2281, 奥拉帕尼, KU0059436
化合物与蛋白结合的复合物	HUMAN ARTD2 (PARP2) - CATALYTIC DOMAIN IN COMPLEX WITH OLAPARIB
分子量	434.46
分子式	C24H23FN4O3
CAS No.	763113-22-0

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 80 mg/mL (184.1 mM)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3017 mL	11.5085 mL	23.0171 mL	57.5427 mL
	5 mM	0.4603 mL	2.3017 mL	4.6034 mL	11.5085 mL
	10 mM	0.2302 mL	1.1509 mL	2.3017 mL	5.7543 mL
	20 mM	0.1151 mL	0.5754 mL	1.1509 mL	2.8771 mL
	50 mM	0.046 mL	0.2302 mL	0.4603 mL	1.1509 mL
	100 mM	0.023 mL	0.1151 mL	0.2302 mL	0.5754 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Prasad CB, et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017 Oct 9;7(1):12876. 2. Miyasaka A, et al. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014 Mar 13;14:179. 3. Murai J, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012 Nov 1;72(21):5588-99. 4. Menear KA, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. 5. Ghonim MA, et al. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med. 2015 Jul 14;13:225.

文献引用

1. Long X, Dai A, Huang T, et al.Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation.ACS nano.2023 2. Valentini E, Di Martile M, Brignone M, et al.Bcl-2 family inhibitors sensitize human cancer models to therapy.Cell Death & Disease.2023, 14(7): 441. 3. Pan X, Zhang W, Wang L, et al.KLF12 transcriptionally regulates PD‐L1 expression in non‐small cell lung cancer.Molecular Oncology.2023 4. Zhao J, Xu J, Wu M, et al.LncRNA H19 Regulates Breast Cancer DNA Damage Response and Sensitivity to PARP Inhibitors via Binding to ILF2.International Journal of Molecular Sciences.2023, 24(11): 9157. 5. Yu L, Zhou D, Zhang G, et al. Co‐occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence. Molecular Oncology.. 2022, 16(3): 607-629. 6. Malka M M, Eberle J, Niedermayer K, et al. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells. Biomolecules. 2021, 11(7): 981. 7. Du T, Zhang Z, Zhou J, et al. A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. Frontiers in pharmacology. 2022, 13. 8. Dai W, Wu J, Peng X, et al. CDK12 orchestrates super‐enhancer‐associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer. Clinical and Translational Medicine. 2022, 12(10): e1087. 9. Guffanti F, Alvisi M F, Anastasia A, et al. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British Journal of Cancer. 2021: 1-9. 10. Wu Y, Wu T, Hu X, et al. Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis. International Journal of Medical Sciences. 2022, 19(2): 233-241.

11. Chiappa M, Guffanti F, Anselmi M, et al. Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers. 2022, 14(7): 1807. 12. Su G, Qin L, Su X, et al. Gender‐dependent pharmacokinetics of olaparib in rats determined by ultra‐high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomedical Chromatography. 2020: e4791. 13. Quan C, Wu Z, Xiong J, et al.Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.Experimental Hematology & Oncology.2023, 12(1): 1-21. 14. Chiappa M, Guffanti F, Grasselli C, et al.Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.International Journal of Molecular Sciences.2024, 25(5): 3049.

下拉查看更多收起

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +

% Tween 80+

% ddH₂O

%DMSO+

计算重置

计算结果如下:

工作液浓度: mg/ml;

母液配置方法: mg 药物溶于 μL DMSO (母液浓度为 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 μL DMSO 主液，加入 μL PEG300，混匀澄清，再加 μL Tween 80，混匀澄清，再加 μL ddH₂O, 混匀澄清。

备注:

要按顺序从左向右依次添加助溶剂。可配合物理方法，如涡流、超声波或热水浴使之帮助溶解。

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到，包括如何准备库存溶液，如何存储产品，以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Olaparib 763113-22-0 Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair Mitophagy PARP AZD2281 Mitochondrial Autophagy inhibit orally Inhibitor 奥拉帕尼 PARP1 KU0059436 poly ADP ribose polymerase PARP2 KU 0059436 AZD-2281 AZD 2281 KU-0059436 inhibitor

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

沪公网安备 31010602006700号

陶术

生物

TargetMol^®中国区唯一合作伙伴

点击进入陶术生物官网

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼

Olaparib

存储

溶解度

溶液配制表

计算器

输入分子式，点击计算，可计算出产品的分子量。

参考文献

文献引用

相关产品

相关化合物库

剂量换算

体内实验配液计算器

技术支持

Keywords